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group B), and HES 70/0.5 (total 7645 L; 7638 L in group A 
and 7 L in group B) were used in both groups (n = 10,850 
and 116). Five percent and 4.4 % albumin (total 1189 L; 
1180 L in group A and 9 L in group B) could be replaced 
by HES 130/0.4 if HES 130/0.4 had been used up to a dose 
of 50 mL/kg.
Conclusion Blood loss (15,111 L) was replaced with 
allogeneic transfusion (53 %), auto-transfusion (12 %), 
albumin (9 %) and HES 70/0.5 (51 %) during surgery in 
April 2012. The predicted volume of 5 and 4.4 % albumin 
saved during this 1-month period if HES 130/0.4 had been 
used up to a dose of 50 mL/kg was 1189 L (86 % of actual 
amount used).
Keywords Transfusion · Volume therapy · Hydroxyethyl 
starch · Albumin
Introduction
Perioperative fluid therapy has shifted from the liberal use 
of crystalloids to goal-directed volume-restricted therapy 
using colloids for blood loss substitution [1–3]. In Japan, 
hydroxyethyl starch (HES) is the preferred colloid during 
surgery with HES 70/0.5 (Hespander®/Salinhes®) being 
the only HES specification available for the past 40 years. 
The maximum daily dosage of HES 70/0.5 has been lim-
ited to 1000 mL. When a higher volume of a colloid solu-
tion was indicated, albumin had to be used instead of 
HES 70/0.5 because new generation of HES had not been 
available in Japan, resulting in increased consumption of 
intraoperative albumin. Third-generation HES 130/0.4 
(Voluven®) has a higher dose limitation (50 mL/kg/day) 
than HES 70/0.5 and was launched in Japan in October 
2013.
Abstract 
Purpose Third-generation hydroxyethyl starch (HES) 
130/0.4 has a larger dose limitation (up to 50 mL/kg/day) 
than HES 70/0.5 (up to 1000 mL/day) which has been used 
in Japan for 40 years. The aim of this study was to survey 
the current intraoperative blood transfusion and volume 
therapy and to predict the possible reduction of intraopera-
tive albumin consumption assuming further replacement 
by HES 130/0.4 using data obtained from a survey by the 
Japanese Society of Anesthesiologists (JSA), although 
HES130/0.4 was not launched in Japan during this survey 
period.
Methods In a JSA survey conducted at JSA-certified hos-
pitals, 12,856 patients with a certain amount of blood loss 
were analyzed for 1 month (April, 2012). The patients were 
divided into two groups—group A included patients aged 
≥11 years and group B included patients aged <10 years. 
The possible lower volume of intraoperative albumin was 
calculated assuming that HES 130/0.4 was used up to a 
dose of 50 mL/kg.
Results Blood loss (total 15,111 L; 15,057 L in group A 
and 54 L in group B) was treated with allogeneic transfu-
sion (total 7970 L; 7893 L in group A and 77 L in group 
B) and auto-transfusion (total 1777 L; 1771 L in group A 
and 6 L in group B) in both groups (n = 11,670 and 119). 
Albumin (total 1391 L; 1376 L in group A and 15 L in 
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In July 2012, 1 year prior to the launch of HES 130/0.4, 
the Japanese Society of Anesthesiologists (JSA) initiated a 
survey for usage of albumin and HES 70/0.5 within JSA-
certified hospitals to document intraoperative infusion and 
transfusion therapy including colloid therapy (HES, albu-
min, and others). The aim of this study was to investigate 
the current status of blood transfusion and colloid therapy 
in operating theaters in Japan and to predict the possible 
reduction of intraoperative albumin volumes assuming that 
colloid volumes up to 50 mL/kg could be replaced by HES 
130/0.4.
Methods
After approval by the ethics committee of the JSA, ques-
tionnaires prepared by the Safety Committee of the JSA 
were sent to 1234 JSA-certified hospitals in 2012. The sur-
vey consisted of two parts. In the first part, the representa-
tives of anesthesiologists at individual hospitals were asked 
to complete a questionnaire on the use of 6 % HES 70/0.5 
and albumin in the operating theater. In the second part, 
data describing transfusion and infusion status of surgical 
patients with intraoperative blood loss of either ≥500 mL 
for patients aged ≥11 years (group A) or with intraopera-
tive blood loss ≥10 mL/kg for patients aged <10 years 
(group B) was derived from a 1-month database (April 
2012).
The database from the second part of the JSA survey 
2012 was the subject of the present study. The results of the 
first part will be presented soon on the official home page 
of JSA.
Unknown blood loss from certain procedures such as 
cardiac surgery with cardio-pulmonary bypass and abdomi-
nal aortic aneurysm surgery with intraoperative autologous 
blood salvage was not counted in the analysis of blood loss. 
Blood loss reported including amniotic fluid in Caesar-
ian section or ascites in abdominal surgery was adopted to 
the blood loss as they were. The amount of transfusion was 
documented in mL, but when units were used, it was calcu-
lated as 140 mL per unit of red blood cells or 120 mL per 
unit of fresh frozen plasma in a standardized way. Platelet 
Alb = 0 S = 0 
HES >= 50ml/kg 
( 50ml/kg̾HES) >= Alb 
S = 0 
S = Alb 







Fig. 1   Algorithm for calculation of possible saving of albumin 
if 6 % HES 130/0.4 had been used up to a total dose of 50 mL/kg 
instead of albumin. Alb intraoperative infusion volume of 5 or 4.4 % 
albumin, HES 6 % HES 70/0.5, S saving volume of albumin. Exam-
ple: If body weight is 60 kg and 5 % albumin (1500 mL) would be 
used, 1st branch of upper Fig. 1 is "no". If HES (1000 mL) would 
be used, the 2nd branch is "no" because HES (1000 mL) is smaller 
than 50 mL/kg (3000 mL/60 kg). The 3rd branch is "yes" because 50 
mL/kg (3000 mL)—HES 1000 mL = 2000 mL which is larger than 
albumin used (1500 mL). This means that HES 130/0.4 could be used 
up to 3000 mL and this amount is larger than HES 70/0.5 (1000 mL) 
plus albumin (1500 mL) used. Then, 1500 mL of albumin used 
could be replaced with HES 130/0.4, consequently saving volume of 
albumin is whole amount of albumin used (1500 mL). If 5 % albu-
min (2500 mL) would be used in the upper example, the 3rd branch 
is "no" because 50 mL/kg (3000 mL)—HES 1000 mL = 2000 mL 
which is smaller than albumin used (2500 mL). Then, 50 mL/kg 
(3000 mL)—HES 1000 mL = 2000 mL which is 80 % of albumin 
used (2500 mL) is the saving volume of albumin
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transfusion was excluded from further analysis as the doc-
umentation could not be clarified (units or mL) in many 
cases.
The algorithm to calculate the volume of 5 and 4.4 % 
albumin that could have been saved if 6 % HES 130/0.4 
was used up to a dose of 50 mL/kg is given in Fig. 1. The 
Cases of blood loss over 500ml (or 10ml/kg in children) 
obtained from the data sheet of the JSA survey n = 12,977
Records excluded by unreliable account n = 100
by missing values   n = 10  
by age unknown n = 11
Database analyzed n = 12,856
Age of 11 and/or older  
n = 12,717
Age less than 10-year-old 
n = 139
Excluded by blood loss below 
500 mL or missing value  
n = 1047
Data analyzed for blood loss 
and transfusion  n = 11,670
Excluded by missing values 
for infusion  n = 1867
Data analyzed for infusion   
n = 10,850
Excluded by blood loss below 
10mL/kg or missing value  
n = 20
Data analyzed for blood loss 
and transfusion  n = 119
Excluded by missing values 
for infusion  n = 23
Data analyzed for infusion   
n = 116
Surgery in April 2012 reported by 707 JSA certified hospitals n = 134,500
Fig. 2  Diagram for data selection
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intraoperative infusion volumes of 20 and 25 % albumin 
were excluded from the above calculations because these 
solutions were mostly used in the priming solution of car-
diopulmonary bypass circuit.
Statistics
All variables were analyzed by descriptive statistical 
analysis.
Results
Seven hundred and seven of 1234 JSA-certified hospitals 
returned valid questionnaires for analysis and reported 
134,500 surgical patients of whom 12,977 matched the 
methodology of this survey. Finally 11,670 patients 
were suitable for analysis for blood loss/transfusion, 
with 10,850 patients being suitable for infusion therapy 
in group A, and 119 patients being suitable for blood 
loss/transfusion and 116 for infusion therapy in group B 
(Fig. 2).
Table 1 shows demographic data in groups A and B. 
Table 2 shows blood loss, allogeneic transfusion, and auto-
transfusion of patients in groups A and B. Total blood loss 
in group A (15,057 L) was treated with allogeneic transfu-
sion (7893 L: 52 % of total blood loss) and auto-transfusion 
(1771 L:12 % of total blood loss), whereas total blood loss in 
group B (54,461 mL) was treated with allogeneic transfusion 
(77,016 mL: 141% of total blood loss) and auto-transfusion 
(6338 mL: 12 % of total blood loss) . It was evident that trans-
fusion therapy dominates in pediatric patients. 
Table 3 shows the total infusion volume including crys-
talloids, colloids, and predicted volume of albumin saved 
in groups A and B. Of 10,850 patients in group A, 1979 
(18 %) were given albumin (5, 4.4, 20, or 25 %), and 8464 
(78 %) were given HES 70/0.5. Of 8464 patients given 
HES 70/0.5, 1518 (18 %) were given >1000 mL HES 
70/0.5 (this is the limitation volume specified in the pack-
age insert). One thousand one hundred eighty liters amount 
of 5 and 4.4 % albumin, which was 86 % of actually 
amount used (1366.2 L), could be replaced by HES 130/0.4 
if HES 130/0.4 had been used up to a dose of 50 mL/kg. 
Of 116 patients in group B, 76 (66 %) were given albumin 
(5, 20, or 25 %), and 45 (39 %) were given HES 70/0.5. It 
became evident that the rate of albumin given was higher 
and the rate of HES given was lower in pediatric patients 
(group B) than those in group A. Nine thousand one hun-
dred seventy four mL amout of 5 % albumin, which was 68 
% of actually amount used (13,446 mL), could be replaced 
Table 1  Demographic data in each group
min minimum, max maximum
Group A Group B
Age (years)
 Valid cases 11,670 cases 119 cases
 Mean (median: min–
max)
57 years (62: 11–104) 1.8 years (0.9: 0–10)
Body weight (kg)
 Valid cases 11, 446 cases 119 cases
 Mean (median: min–
max)
60.2 kg (59.6: 
30.1–138.7)
9.7 kg (7.7: 1.7–36.1)
Table 2  Blood loss, allogeneic 
transfusion, and auto-
transfusion
Valid cases of blood loss indicates blood loss ≥500 mL in group A and 10 mL/kg in group B. Valid cases 
of allogeneic and auto transfusion indicates over 0 mL. Allogeneic transfusion included red blood cell 
concentrate and fresh frozen plasma but not platelet concentrate. Auto-transfusion included preoperative 
donated autologous transfusion, intraoperative hemodilution autologous transfusion, and intraoperative 
blood cell salvage transfusion, min minimum; max maximum, () in group B: values in mL/kg
Group A Group B
Blood loss
 Valid cases 11,670 cases 119 cases
 Total amount 15,057 L 54,461 mL
 Mean (median: min–max) 1292 mL (911: 500–44,950) 458 mL(59) [300 (37): 17 (10)–2890 (389)]
Allogeneic transfusion
 Valid cases 5634 cases 104 cases
 Total amount 7893 L 77,016 mL
 Mean (median: min–max) 1401 mL (800: 1–48,300) 741 mL (367: 27–5958)
Auto-transfusion
 Valid cases 2624 cases 32 cases
 Total amount 1771 L 6338 mL
 Mean (median: min–max) 675 mL (500: 1–15,500) 198 mL (148: 4–1030)
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by HES 130/0.4 if HES 130/0.4 had been used up to a dose 
of 50 mL/kg.
The calculation of the total predicted volume of albu-
min saved for 5 and 4.4 % albumin in groups A and B was 
1189 L in April 2012. This predicted volume of albumin 
saved (1189 L) corresponds to 86.2% of actual amount of 
4.4 and 5% albumin (1379 L) used during this period.
The JSA survey 2012 revealed that 15,111 L of blood 
loss were replaced with 7970 L of allogeneic transfusion, 
1777 L of auto-transfusion, 1391 L of albumin, and 7645 L 
of HES 70/0.5 during surgery in April 2012. The predicted 
volume of 5 and 4.4 % albumin saved was 1189 L which 
was 86 % of actual amount used during this 1-month period 
if HES 130/0.4 had been used up to a dose of 50 mL/kg.
Discussion
The present survey is a unique study of a large database 
obtained from 707 JSA-certified hospitals to describe the 
current blood loss/transfusion and colloid therapy during 
surgery in Japan. The results of this survey may lead to a 
new strategy for intraoperative volume therapy.
HES has been used for perioperative volume replace-
ment as a plasma substitute in operating theaters and inten-
sive care units. We should consider two aspects for perio-
perative use of HES. First, HES can reduce intraoperative 
fluid loading. Recent intraoperative fluid management has 
changed from the liberal infusion strategy of extracel-
lular fluid to a relatively goal-directed volume-restricted 
Table 3  Total infusion volume, 
colloids volume, and predicted 
volume of albumin saved
Total infusion volume included crystalloids and colloids. Other artificial colloid was only dextran. 20 and 
25 % albumin were ineligible for analysis of "Albumin saved by HES 130/0.4"; min minimum, max maxi-
mum, () in group B: values in mL/kg
Group A Group B
Total infusion volume
 Valid cases 10,850 case 116 cases
 Total amount 32,283.3 L 87,431 mL
 Mean (median: min–max) 2975 mL (2500: 50–42,940) 754 mL (361: 17–6940)
5 % albumin
 Valid cases 1751 cases 53 cases
 Total amount 1280.0 L 13,446 mL
 Mean (median: min–max) 731 mL (500: 4–9500) 254 mL (110: 20–1650)
4.4 % albumin
 Valid cases 133 cases 0 case
 Total amount 86.2 L –
 Mean (median: min–max) 648 mL (500: 100–3500) –
20 % albumin
 Valid cases 15 cases 2 cases
 Total amount 2.5 L 16 mL
 Mean (median: min–max) 163 mL (100: 50–1000) 8 mL (8: 8–8)
25 % albumin
 Valid cases 80 cases 21 cases
 Total amount 7.0 L 1640 mL
 Mean (median: min–max) 88 mL (100: 30–250) 78 mL (80: 50–130)
HES70/0.5
 Valid cases 8464 cases 45 cases
 Total amount 7637.5 L 7131 mL
 Mean (median: min–max) 902 mL (,000: 10–12,500) 159 (12) mL [62 (8): 10 (1)–1000 (61)]
Other artificial colloids
 Valid cases 295 cases 0 case
 Total amount 195.5 L –
 Mean (median: min–max) 663 mL (500: 50–2000) –
Albumin saved by HES130/0.4
 Valid cases 1817 cases 52 cases
 Total amount 1180.1 L 9174 mL
 Mean (median: min–max) 650 mL (500: 4–3350) 176 mL (100: 20–905)
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strategy using HES. Lowell et al. demonstrated that weight 
gain from fluid overloading during surgery correlated to 
high mortality rates [4]. Enhanced recovery after surgery 
consensus guideline [5, 6] specified “Intraoperative fluids 
should be balanced to avoid both hypo- and hypervolemia. 
Intraoperative goal directed fluid therapy should be consid-
ered on an individual basis”. In surgical use, HES (espe-
cially third-generation HES 130/0.4) demonstrated good 
outcomes for transfusion rate [7], mortality [8], and renal 
function [7]. HES still plays a major role in goal-directed 
intraoperative fluid therapy.
Second, HES 130/0.4 can reduce intraoperative albumin 
consumption because higher doses can be given compared 
to HES 70/0.5. Japan has not only been criticized for large 
albumin consumption, but also for high cost excessive peri-
operative albumin usage. The present study focused on this 
second issue.
The present study represents a large sample of 123,500 sur-
gical patients with 10,966 patients (10,850 patients in group A 
and 116 patients in group B) being suitable for analysis.
Approximately 64 % of blood loss was replaced by 
allogeneic (52 %) and auto-transfusion (12 %). In group 
A, the auto-transfusion rate was 30 % of all transfusions, 
which was thought to be very high; however, in group B, 
141 % of blood loss was replaced by allogeneic transfu-
sion. There are two possible reasons. One reason is that a 
small volume of blood loss leads to hypovolemia and an 
unstable hemodynamic state in small children. In such sit-
uations, anesthesiologists tend to decide on early transfu-
sion. Another reason is that the smaller the blood loss, the 
higher the difference between the actual blood loss and 
the measured blood loss because of drying gauze with the 
blood to be measured, and immeasurable blood absorbed 
by cover sheets or spilt on the floor. Anesthesiologists 
then tend to assess the volume status based on estimated 
blood loss rather than measured blood loss by the nurse.
The predicted volume of 5 and 4.4 % albumin saved was 
1189 L in 1 month. This would amount to approximately 
14,300 L over 1 year. Based on the statistics from the Ministry 
of Health, Labor and Welfare 2012 (http://www.mhlw.go.jp/
stf/shingi/2r9852000002hs9l.html), the total number of surger-
ies performed in 1648 diagnosis procedure combination (DPC) 
hospitals during a 6-month period was 2,045,932, which is 2.8 
times higher than the source of the present study (123,500 in 
1 month). Approximately 40,000 L (14,300 L × 2.8) of albu-
min would be saved in a year. The consumption of albumin in 
Japan in 2009 was 1460,000 L (http://www.mhlw.go.jp/new-
info/kobetu/iyaku/kenketsugo/2q/pdf/5-2.pdf). As a result of 
this analysis, 2.7 % (40,000/1,460,000) of total albumin con-
sumption could be saved in operating theaters.
The principle proof of this analysis was recently sup-
ported by a pilot study [8] as well by a study of surgical 
patients [9]. Blood loss and transfusion requirements in 
cardiac surgery were higher for albumin compared to HES 
130/0.4 [10]. Albumin administration in cardiac surgery 
was associated with a dose-dependent risk of acute kidney 
injury, whereas 6 % HES 130/0.4 was not [11]. Albumin 
administration for critically ill patients did not improve 
mortality or morbidity even for hypoalbuminemia patients 
[12]. Based on these findings, third-generation HES 130/0.4 
may become a major colloid for perioperative volume ther-
apy instead of albumin. In cases of massive administration 
of HES 130/0.4 and also of albumin, however, dilutional 
coagulopathy should be monitored and treated appropriately 
with fresh frozen plasma and platelet concentrate.
Limitation of the study
1. As anesthesiologists may not use up to the maximum 
dose of HES 130/0.4 in cases of bleeding during sur-
gery, the calculation of the possible volume of saved 
albumin may be overestimated.
2. The intraoperative infusion volume of 20 and 25 % 
albumin was excluded from the possible saving volume 
of albumin as it was mostly used in the priming solu-
tion of cardiopulmonary bypass circuit. This albumin, 
however, could also be replaced by HES 130/0.4 as the 
colloid for priming solution.
Conclusion
Based on data from the 2012 JSA survey, 15,111 L of blood 
loss were replaced with 7970 L of allogeneic transfusion, 
1777 L of auto-transfusion, 1391 L of albumin, and 7645 L 
of HES 70/0.5 during surgery in April 2012. The predicted 
volume of 5 and 4.4 % albumin saved was 1189 L (86 % 
of actual amount used) during this 1-month period if HES 
130/0.4 had been used up to a dose of 50 mL/kg.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Gan TJ, Soppitt A, Maroof M, El-Moalem H, Robertson KM, 
Moretti E, Dwane P, Glass PS. Goal-directed intraoperative fluid 
administration reduces length of hospital stay after major sur-
gery. Anesthesiology. 2002;97(4):820–6.
 2. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, 
Matot I. Effect of intraoperative fluid management on outcome 
after intraabdominal surgery. Anesthesiology. 2005;103(1):25–32.
390 J Anesth (2016) 30:384–390
1 3
 3. Ghneim MH, Regner JL, Jupiter DC, Kang F, Bonner GL, 
Bready MS, Frazee R, Ciceri D, Davis ML. Goal directed fluid 
resuscitation decreases time for lactate clearance and facilitates 
early fascial closure in damage control surgery. Am J Surg. 
2013;206(6):995–9 (discussion 999–1000).
 4. Lowell J, Schifferdecker C, Driscoll D, Benotti P, Bistrian B. 
Postoperative fluid overload: not benign problem. Crit Care Med. 
1990;18:728–33.
 5. Fearon KCH, Ljungqvist O, Von Meyenfeldt M, Revhaug A, 
Dejong CHC, Lassen K, Nygren J, Hause J, Soop M, Andersen J, 
Kehlet H. Enhanced recovery after surgery: a consensus review 
of clinical care for patients undergoing colonic resection. Clin 
Nutr. 2005;24(3):466–77.
 6. Varadhan KK, Neal KR, Dejong CHC, Fearon KCH, Ljungqvist 
O, Lobo DN. The enhanced recovery after surgery (ERAS) path-
way for patients undergoing major elective open colorectal sur-
gery: a meta-analysis of randomized controlled trials. Clin Nutr. 
2010;29(4):434–40.
 7. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, 
Gillespie RS. Resuscitation with hydroxyethyl starch improves 
renal function and lactate clearance in penetrating trauma in a 
randomized controlled study: the FIRST trial (fluids in resuscita-
tion of severe trauma). Br J Anaesth. 2011;107(5):693–702.
 8. Morioka N, Ozaki M, Yamakage M, Morimatsu H, Suzuki Y, 
Bepperling F, Miyao H, Namiki A, Morita K. The volume effect 
and safety of 6 % hydroxyethyl starch 130/0. 4 in patients under-
going major elective surgery : an uncontrolled, open-labeled, 
multi-center study. Open J Anesthesiol. 2013;3:326–37.
 9. Van Der Linden P, James M, Mythen M, Weiskopf RB. 
Safety of modern starches used during surgery. Anesth Analg. 
2013;116(1):35–48.
 10. Jacob M, Fellahi J, Chappell D, Kurz A. The impact of hydrox-
yethyl starches in cardiac surgery—a meta-analysis. Crit Care. 
2014;18:656.
 11. Frenette AJ, Bouchard J, Bernier P, Charbonneau A, Nguyen LT, 
Rioux JP, Troyanov S, Williamson DR. Albumin administration 
is associated with acute kidney injury in cardiac surgery : a pro-
pensity score analysis. Crit Care. 2014;18(6):602.
 12. Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G. 
Human albumin solution for resuscitation and volume expan-
sion in critically ill patients. Cochrane Database Syst Rev. 
2011;11:CD001208.
